Immunocore Holdings (IMCR) Total Liabilities (2019 - 2026)

Immunocore Holdings has disclosed Total Liabilities across 8 years of filings, most recently posting $678.4 million for Q1 2026.

• Total Liabilities for Q1 2026 came in at $678.4 million, up 4.45% year-over-year; the trailing twelve-month figure through Mar 2026 was $678.4 million (up 4.45% YoY), and the FY2025 annual result was $686.2 million, up 5.77% from the prior year.
• Total Liabilities came in at $678.4 million for Q1 2026 at Immunocore Holdings, down from $686.2 million in the prior quarter.
• In the past five years, Total Liabilities ranged from a high of $706.8 million in Q3 2024 to a low of -$356.0 million in Q3 2023.
• The 5-year median for Total Liabilities is $649.2 million (2024), against an average of $388.0 million.
• Across the five-year window, Total Liabilities surged 298.56% in 2024 and retreated 0.12% in 2025, its largest moves.
• Immunocore Holdings' Total Liabilities stood at $183.9 million in 2022, then increased by 24.09% to $228.2 million in 2023, then surged by 184.36% to $648.8 million in 2024, then advanced by 5.77% to $686.2 million in 2025, then retreated by 1.14% to $678.4 million in 2026.
• The last three Total Liabilities figures came in at $678.4 million (Q1 2026), $686.2 million (Q4 2025), and $705.9 million (Q3 2025), per Business Quant data.